Machine learning-based transcriptomic signatures predict treatment outcomes across targeted therapy and immunotherapy regimens in renal cell carcinoma key findings:
🔹RNA-based signatures outperformed IMDC risk groups for PFS and OS stratification
🔹Treatment-specific transcriptomic models predicted binary outcome disease control vs progression
🔹Molecular signatures provided prognostic information beyond standard clinical risk models
🔹Supports development of precision oncology tools to personalize RCC treatment selection
📜asco.org/abstracts-pres…
📽️hasanov-lab.github.io/gallery/
Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases @BetulGokYavuz1@ASCO#ASCO26
Key findings:
🧠RCC brain metastases harbor distinct copy-number alterations (CNAs) compared with primary tumors.
🧬Recurrent alterations involving 8p loss, 8q gain, and 9p21.3 deletionwere enriched in brain metastases across all cancers.
📈These CNA patterns were associated with worse survival and may contribute to brain metastatic progression.
🤖Using genomic features, we developed a machine learning model that identified patients at increased risk of mortality/brain metastasis.
Key findings of @ShriyaDeshmukh3 presentation at #ASCO26, the spatial transcriptomic profiling of the tumor microenvironment in metastatic RCC treated with sunitinib:
🔹Sunitinib resistance is associated with a profoundly immunosuppressive TME
🔹Enrichment of myeloid suppressive programs (SPP1+ macrophages)and T-cell exhaustion
🔹Increased angiogenesis, extracellular matrix remodeling, and hypoxia-related pathways
🔹Adaptive metabolic reprogramming emerges in resistant tumors
🔹Machine learning-derived spatial signatures predicted survival in an independent external cohort
@tompowles1@Uromigos@DrChoueiri Impressive to see the absolute risk reduction with pembrolizumab at 24 months in ctDNA+ group is 20%, vs in ctDNA- group is 7%. A new chapter for RCC adjuvant care with hopefully more sensitive tests soon. Congrats @DrChoueiri and team for this great study!
🚨🚨Multiple Brain Mets Randomized Trial🚨
· Significantly less symptom burden with SRS compared to HA-WBRT
· Better ADL, cognition & KPS after SRS
· SRS Standard of Care 5-20 brain mets
jamanetwork.com/journals/jama/…
Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity.
pubmed.ncbi.nlm.nih.gov/41378983/
As 2025 comes to a close, @David_Cohn_MD, @DrRPollock and I thought we’d take a moment to celebrate stories this year that show why @OSUCCC_James is such a powerhouse against cancer.
Here is a thread of 25 inspiring cancer stories in '25:
🧵
Happening now! The 7th Annual #PIIO Symposium Poster Session at Marriott OSU (3100 Olentangy River Rd, Cbus, OH). 🚀 Much more to come with the reception & Director's Address by Dr. @Zihai Li! @OSUCCC_James@Pelotonia#Immuno_Oncology
539 Followers 563 FollowingNCC Japan Official Account approved in Dec. 2025. Dr. Hamamoto: Division Chief (NCC)/Team Director (RIKEN)/Professor of NCC Medical Science (Science Tokyo).
308 Followers 535 FollowingDirector of Neuro-Oncology @RutgersCancer, System Leader for Neuro-Oncology @RWJBarnabas #NeuroOncology #GBM Scientist. Advocate. Mom. Opinions are my own.
606 Followers 2K FollowingAssistant Professor and Cancer Biologist @WeillCornell || Big Fan of: R Programming & Data Science ||🥋 || 🎾 || ⛷ Opinions My Own & RTs ≠ Endorsements
335 Followers 948 FollowingTenure Track Fellow (Group Leader) at @LivUniISMIB. Studying cancer metabolism, mitochondria, metabolite signalling. Views are my own.
836 Followers 7K FollowingFocus on healthcare, life sciences, medical, and technology sectors. I also help athletes and military veterans become entrepreneurs, executives and investors.
288 Followers 408 FollowingMD-PhD student at the University at Buffalo & Roswell Park Comprehensive Cancer Center
Certified goofball interested in kidney cancer & tumor immunology
98 Followers 395 FollowingAtlantic Canada’s trusted voice for pancreatic cancer. Supporting Canadians living with pancreatic cancer, caregivers, and advancing research & care.
7K Followers 2K FollowingCEO, @OSUCCC_James. Physician-scientist, kidney cancer student, reader/writer, explorer of medicine and medical education. She/her. Views are my own.
16K Followers 14K FollowingAssistant Dean, Chair of the Faculty, & Associate Professor of Marketing @EKU_CoB | Research Areas: Pricing, Branding, Sports Marketing, & Education
3K Followers 121 FollowingNews from Joan Massagué lab at @MSKCancerCenter. Tweets from lab members and not Joan Massagué unless signed JM. Tweets represent personal views only.
10K Followers 3K FollowingFollow us for updates on the latest American Cancer Society research to help prevent, fight and cure cancer.
https://t.co/Y9sAPyOasI
777 Followers 520 FollowingI review your statistics for a living. Director of Data Analytics @UmichUrology · Managing Stat Editor @EUplatinum · #GoBlue
539 Followers 563 FollowingNCC Japan Official Account approved in Dec. 2025. Dr. Hamamoto: Division Chief (NCC)/Team Director (RIKEN)/Professor of NCC Medical Science (Science Tokyo).
11K Followers 2K FollowingAs the flagship journal of the American Cancer Society, CA publishes the latest cancer statistics, ACS guidelines, and reviews on the current state of cancer.
308 Followers 535 FollowingDirector of Neuro-Oncology @RutgersCancer, System Leader for Neuro-Oncology @RWJBarnabas #NeuroOncology #GBM Scientist. Advocate. Mom. Opinions are my own.
1K Followers 171 FollowingChair of Plastic and Reconstructive Surgery at @OhioStateMed, Surgeon-scientist, Mother & Wife. Tweeting about #OSUPlastics, nerve #research, #nervesurgery.
8K Followers 4K FollowingRadiation Oncologist |
Med Director of Digital Engagement @NorthwellHealth Cancer Institute | CEO @JOWMA_med | Volunteer @ASCO @ASTRO_org @NRGonc
10K Followers 2K FollowingThe official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Editor-in-Chief: Michael T. Lotze, MD
5K Followers 471 FollowingTrends in Cancer is a leading reviews journal covering advances in cancer research and oncology published by Cell Press. Tweets by Editor Danielle Loughlin.
4K Followers 958 FollowingAssociate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
606 Followers 2K FollowingAssistant Professor and Cancer Biologist @WeillCornell || Big Fan of: R Programming & Data Science ||🥋 || 🎾 || ⛷ Opinions My Own & RTs ≠ Endorsements
335 Followers 948 FollowingTenure Track Fellow (Group Leader) at @LivUniISMIB. Studying cancer metabolism, mitochondria, metabolite signalling. Views are my own.
6K Followers 916 FollowingExecutive Director @WinshipAtEmory | Professor @EmoryUniversity |Associate VP for Cancer, Woodruff Health Sciences Center I Opinions are my own.
83K Followers 360 FollowingStudent of causal inference, human reasoning, and history of ideas, all viewed through the sharp lens of artificial intelligence.
531 Followers 650 FollowingAssoc. Prof. for Dermatology @UniklinikEssen,Alumni @SJMorrison_ . Physician-Scientist. Emmy Noether Fellow,@ERC_Research, Focus on Cancer Metabolism/Metastasis
2K Followers 539 FollowingConnecting you to Ohio State communities through convergent, ground-breaking research, problem-solving innovation, knowledgeable resources and entrepreneurship.
4.9M Followers 4 FollowingOpenAI’s mission is to ensure that artificial general intelligence benefits all of humanity. We’re hiring: https://t.co/dJGr6LgzPA
288 Followers 408 FollowingMD-PhD student at the University at Buffalo & Roswell Park Comprehensive Cancer Center
Certified goofball interested in kidney cancer & tumor immunology
16K Followers 14K FollowingAssistant Dean, Chair of the Faculty, & Associate Professor of Marketing @EKU_CoB | Research Areas: Pricing, Branding, Sports Marketing, & Education